Our scientists use a disciplined, sophisticated, biology-driven approach to advance our current pipeline of four clinical-stage products as we leverage our R&D capabilities to identify and develop new drugs. Below you can review the scientific publications for each of the product candidates in our promising pipeline.

Daclizumab

Elotuzumab (HuLuc63)

TRU-016

Volociximab (M200)

PDL192